Opendata, web and dolomites

DesignerAntibiotics

Towards the prevention of aminoglycoside antibiotic-related deafness

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DesignerAntibiotics project word cloud

Explore the words cloud of the DesignerAntibiotics project. It provides you a very rough idea of what is the project "DesignerAntibiotics" about.

biology    children    intensive    acquisition    human    compounds    journal    amounts    suffer    drawback    publication    annually    mitochondrial    cells    100    murine    annual    models    chemically    infancy    22    incidence    aminoglycoside    effect    masters    bacteria    molecular    urgent    university    care    imperial    author    phd    incurred    78    irreversible    despite    potency    billion    impedes    15    life    resistance    distinction    caused    modify    london    occurs    20    shown    maintaining    patients    aminoglycosides    candidate    inner    safer    die    diminish    group    first    impairment    damage    profound    gt    college    stanford    rare    vitro    profoundly    antibacterial    biobank    patient    drug    dna    patented    infections    ototoxicity    hearing    million    crystallography    25    critically    economically    exposed    threatening    resistant    antimicrobials    language    class    treatment    limits    structural    generation    neonatal    investigation    published    clinical    mutation    antibiotics    1555a    data    ear    guided    ucl    deaf    genetics   

Project "DesignerAntibiotics" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE LONDON 

Organization address
address: GOWER STREET
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 251˙857 €
 EC max contribution 251˙857 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-02-13   to  2020-02-12

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 251˙857.00
2    BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY US (STANFORD) partner 0.00

Map

 Project objective

Aminoglycosides are critically important antimicrobials used in the treatment of life-threatening infections. A major drawback of usage is hearing loss caused by irreversible damage to the inner ear (ototoxicity). Ototoxicity occurs in ~20% of patients and ~100% of patients with the m.1555A>G mitochondrial DNA mutation. The largest EU patient group exposed to aminoglycosides are children in neonatal intensive care and the effect of hearing loss during infancy is particularly profound as it impedes language acquisition. Thus, there is an urgent need to develop safer aminoglycoside antibiotics. Ototoxicity limits usage despite the antibacterial potency and low incidence of drug resistance provided by this class of antibiotics. Economically, the annual EU cost incurred by drug resistant infections amounts to €1.5 billion, and the cost of hearing impairment is estimated to be €78 billion. Moreover, 25,000 EU patients die annually as a result of infections caused by resistant bacteria and 22.5 million suffer from hearing impairment, with 2 million profoundly deaf.

Stanford research recently published in the Journal of Clinical Investigation has shown that it is possible to chemically modify aminoglycosides to diminish ototoxicity while maintaining antibacterial activity. Through a novel collaboration between Stanford and University College London (UCL), the aim of this research is to use a results-guided drug design approach to develop the next generation of safer aminoglycoside antibiotics. For this work, the candidate will have access to 15 novel patented aminoglycoside compounds, crystallography data, murine in vitro and in vitro models of ototoxicity, and a rare biobank of cells from patients with the m.1555A>G mutation. This work will build upon the candidate’s Distinction Masters of Research structural biology experience at Imperial College London, and UCL PhD and recent first-author publication in Human Molecular Genetics related to aminoglycoside ototoxicity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DESIGNERANTIBIOTICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DESIGNERANTIBIOTICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

DIGILEAD (2020)

Digital leadership, well-being and performance in organizations

Read More  

Photonic Radar (2019)

Implementation of Long Reach Hybrid Photonic Radar System and convergence over FSO and PON Networks

Read More  

CLIMACY (2020)

Practices of Climate Diplomacy and Uneven Policy Responses on Climate Change on Human Mobility

Read More